Elvira Kinzina

Elvira Kinzina

Auto-generated profile, based on publicly available information

Elvira Kinzina

McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2022 in Cell Reports Methods
Verified
Journal Article
Open access
EAErik Aznauryan
Erik Aznauryan
AYAlexander Yermanos
Alexander Yermanos
EKElvira Kinzina
Elvira Kinzina
ADAnna Devaux
Anna Devaux
EKEdo Kapetanovic
Edo Kapetanovic
SRSai T. Reddy
Sai T. Reddy
Existing approaches to therapeutic gene transfer are marred by the transient nature of gene expression following non-integrative gene delivery and by safety concerns due to the random mechanism of viral-mediated genomic insertions. The disadvantages of these methods encourage future research in identifying human genomic sites that allow for durable and safe expression of genes of interest. We conducted a bioinformatic search followed by the experimental characterization of human genomic sites, identifying two that demonstrated the stable expression of integrated reporter and therapeutic genes without malignant changes to the cellular transcriptome. The cell-type agnostic criteria used in our bioinformatic search suggest widescale applicability of identified sites for engineering of a diverse range of tissues for clinical and research purposes, including modified T cells for cancer therapy and engineered skin to ameliorate inherited diseases and aging. In addition, the stable and robust levels of gene expression from identified sites allow for the industry-scale biomanufacturing of proteins in human cells.

5 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
EAErik Aznauryan
Erik Aznauryan
AYAlexander Yermanos
Alexander Yermanos
EKElvira Kinzina
Elvira Kinzina
EKEdo Kapetanovic
Edo Kapetanovic
DMDenitsa Milanova
Denitsa Milanova
SRSai T. Reddy
Sai T. Reddy
Summary: Existing approaches for the integration and expression of genes of interest in a desired human cellular context are marred by the safety concerns related to either the random nature of viral-mediated integration or unpredictable pattern of gene expression in currently employed targeted genomic integration sites. Disadvantages of these methods lead to their limited use in clinical practice, thus encouraging future research in identifying novel human genomic sites that allow for predictable and safe expression of genes of interest. We conducted a bioinformatic search followed by experimental validation of novel genomic sites and identified two that demonstrated stable expression of integrated reporter and therapeutic genes without detrimental changes to cellular transcriptome. The cell-type agnostic criteria used in our bioinformatic search suggest wide-scale applicability of our sites for engineering of a diverse range of tissues for therapeutic as well as enhancement purposes, including modified T-cells for cancer therapy and engineered skin to ameliorate inherited diseases and aging. Additionally, the stable and robust levels of gene expression from identified sites allow for their use in industry-scale biomanufacturing of desired proteins in human cells.